TAK-603 - CAS 158146-85-1
Catalog number: 158146-85-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
TAK-603, a quinoline derivative, has been found to be an immunomodulator that was once studied in sorts of inflammatory diseases.
TAK-603, TAK603, TAK 603; Ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate; UNII-W6RZK26FCB; W6RZK26FCB; AC1L4BH6
Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).
Quality Standard:
In-house standard
Canonical SMILES:
1.TAK-603, an anti-inflammatory compound, reduces crescentic glomerulonephritis and preserves renal function in WKY rats.
Yamahana J;Wada T;Furuichi K;Sakai N;Yokoyama H;Kaneko S Nephrol Dial Transplant. 2006 Oct;21(10):2736-44. Epub 2006 Aug 5.
BACKGROUND: ;The therapeutic efficacy of the regulation of T helper (Th)-1-predominant immune responses remains to be investigated. Therefore, the effects of the anti-inflammatory compound TAK-603 were investigated in a model of crescentic glomerulonephritis induced by a small dose of nephrotoxic serum in Wistar-Kyoto rats.;METHODS: ;TAK-603 (50 mg/kg body weight) was administered orally, starting at the time of induction of glomerulonephritis. In group 1, the drug was administered daily for the initial 6 days. TAK-603 was administered on day 0 only in group 2, and from day 3 to 5 in group 3. In each group, nephritic rats were killed on days 6 and 56.;RESULTS: ;In group 1 consisting of rats treated with TAK-603 daily from day 0 to 5, glomerular damage, including crescent formation, was improved on day 6, with reductions in the numbers of CD4, CD8 and ED-1 positive cells, as well as in urinary protein excretion. Protein and transcript levels of Th1 cytokines in the diseased kidneys were markedly decreased by TAK-603 treatment. Renal pathology, including glomerulosclerosis and interstitial fibrosis, was ameliorated and proteinuria was markedly decreased. Elevated levels of serum creatinine showed concomitant improvement.
2.Reduction of disease causative T-cells in experimental autoimmune disease models by a new antirheumatic drug, TAK-603.
Ohta Y;Fukuda S;Makino H Immunopharmacology. 1997 Oct;37(2-3):167-74.
We investigated the mode of action of a new quinoline derivative, TAK-603 (ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmeth yl) quinoline-3-carboxylate), in adjuvant arthritis (AA), a model of rheumatoid arthritis. AA rat splenocytes transferred the arthritis to normal syngeneic rats upon inoculation, but the cells from AA rats treated with TAK-603 (6.25 mg/kg/day) caused only mild arthritis with significantly less foot pad swelling and a lower arthritis score. An effect of TAK-603 in the induction phase of AA was suggested. TAK-603 had little effect on CD4+ and CD8+ T-cell populations in the AA rat splenocytes. We therefore estimated the frequency of T-cells which are reactive to the so-called disease causative antigen using a limiting dilution assay (LDA). The ratio of T-cells responsive to PPD, which increased in AA rat splenocytes with the severity of the arthritis, was reduced in AA rats treated with TAK-603. Furthermore, the ratio of MBP (myelin basic protein)-reactive T-cells, which were generated in experimental allergic encephalomyelitis (EAE) rats, were also reduced by TAK-603 administration. These data suggest that TAK-603 acts on the immune system and reduces the number of cells reactive to the relevant antigen.
3.Possible factor for nonlinear pharmacokinetics of TAK-603, a new antirheumatic agent, in rats.
Tagawa Y;Miwa K;Yamashita K;Tsukuda R;Yoshimura Y;Tanayama S;Tanigawara Y Biopharm Drug Dispos. 1999 Jan;20(1):11-8.
A new antirheumatic, TAK-603, shows nonlinear pharmacokinetics in both animals and humans. To elucidate the mechanism of these nonlinear pharmacokinetics, in vivo and in vitro metabolism of 14C-labeled TAK-603 ([14C]TAK-603) was studied using rats as these resemble humans in their metabolic profiles. After intravenous injection of [14C]TAK-603 to rats at doses of 1, 5, and 15 mg kg(-1), the total body clearance of unchanged drug decreased significantly with increasing dose, whereas the apparent distribution volume did not alter remarkably. Thus, saturation in the elimination processes was considered to be a factor responsible for the nonlinear pharmacokinetics. The disappearance of unchanged drug from the circulation, however, followed a dose-dependent first-order process, indicating that the nonlinearity observed was not merely due to saturation of the elimination capacity. In vitro studies using rat liver microsomes showed that TAK-603 competitively inhibited CYP-catalysed nifedipine oxidation and also that the demethylated metabolite M-I, the major metabolite in rats and humans, competitively inhibited the oxidation of nifedipine. These results suggested that inhibition by M-I of the metabolism of the parent drug (i.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 78739-01-2 D-AP4

(CAS: 78739-01-2)

D-AP4 has been found to be an excitatory amino acid receptor antagonist as well as an agonist at the quisqualate-sensitized AP6 site.

CAS 110140-89-1 Ridogrel

(CAS: 110140-89-1)

Ridogrel is a thromboxane synthase inhibitor used for the prevention of systemic thrombo-embolism. It is also a receptor antagonist that may be used as an adjun...

(CAS: 724741-75-7)

STF-31 is a selective glucose transporter GLUT1 inhibitor.

CAS 886992-99-0 Ac-Gly-BoroPro

(CAS: 886992-99-0)

A selective FAP inhibitor (Ki= 23 nM)

CAS 106392-48-7 ST271

(CAS: 106392-48-7)

A potent inhibitor of protein tyrosine kinase (PTK)

CAS 41708-72-9 ToCainide

(CAS: 41708-72-9)

Tocainide, a lidocaine analog, is a class Ib antiarrhythmic agent.

CAS 470-37-1 Cinobufagin

(CAS: 470-37-1)

Cinobufagin can inhibit the proliferation of U-2OS cells, and induce cell apoptosis. The potential mechanism of Cinobufagin-induced apoptosis may be related to ...

CAS 1253186-56-9 GSK-7975A

(CAS: 1253186-56-9)

This active molecular is a calcium release-activated calcium modulator (ORAI1) inhibitor. GSK-7975A inhibited toxin-induced activation of ORAI1 and/or activatio...

Quick Inquiry

Verification code

Featured Items